Down-regulated donor-specific T-cell reactivity during successful tapering of immunosuppression after kidney transplantation
Open Access
- 2 May 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 128 (2) , 388-393
- https://doi.org/10.1046/j.1365-2249.2002.01810.x
Abstract
Stable cadaveric renal transplant patients were routinely converted from cyclosporin A (CsA) to either azathioprine (AZA) or mycophenolate mofetil (MMF) 1 year after transplantation to reduce the side effects of long‐term immunosuppressive therapy. Thereafter, the AZA and MMF dose was gradually tapered to 50% at 2 years after transplantation. We questioned whether a reduction of immunosuppressive treatment results in a rise of donor‐specific T‐cell reactivity. Before transplantation (no immunosuppression), 1 year (high dose immunosuppression) and 2 years (low dose immunosuppression) after transplantation, the T‐cell reactivity of peripheral blood mononuclear cells (PBMC) against donor and third‐party spleen cells was tested in mixed lymphocyte cultures (MLC) and against tetanus toxoid (TET) to test the general immune response. We also measured the frequency of donor and third‐party reactive helper (HTLpf) and cytotoxic (CTLpf) T‐lymphocyte precursors in a limiting dilution assay. Donor‐specific responses, calculated by relative responses (RR = donor/third‐party reactivity), were determined. Comparing responses after transplantation during high dose immunosuppression with responses before transplantation (no immmunosuppression), the donor‐specific MLC‐RR (P = 0·04), HTLp‐RR (P = 0·04) and CTLp‐RR (P = 0·09) decreased, while the TET‐reactivity did not change. Comparing the responses during low dose with high dose immunosuppression, no donor‐ specific differences were found in the MLC‐RR, HTLp‐RR and CTLp‐RR, although TET‐reactivity increased considerably (P = 0·0005). We observed a reduction in donor‐specific T‐cell reactivity in stable patients after renal transplantation during in vivo high dose immunosuppression. Tapering of the immunosuppressive load had no rebound effect on the donor‐specific reactivity, while it allowed recovery of the response to nominal antigens.Keywords
This publication has 41 references indexed in Scilit:
- Rebound effect of the allogenic T-cell response to donor and third-party lymphocytes after cyclosporine withdrawal in renal transplant recipientsTransplant Immunology, 1998
- Immunologic function and survival in hemodialysis patientsKidney International, 1998
- STEROID WITHDRAWAL IN MYCOPHENOLATE MOFETIL-TREATED RENAL ALLOGRAFT RECIPIENTSTransplantation, 1997
- Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantationThe Lancet, 1995
- Induction of donor-pecific tolerance or sensitization as measured by sequential MLC reactivity up to 24 months after renal transplantationTransplant International, 1994
- Clinical significance of in vitro donor-specific hyporesponsiveness in renal allograft recipients as demonstrated by the MLRTransplant International, 1994
- A rapid limiting dilution assay for measuring frequencies of alloreactive, interleukin-2-producing T cells in humansJournal of Immunological Methods, 1992
- Comparison of Three Immunosuppressive Regimens in Cadaver Renal Transplantation: Long-Term Cyclosporine, Short-Term Cyclosporine Followed by Azathioprine and Prednisolone, and Azathioprine and Prednisolone without CyclosporineNew England Journal of Medicine, 1988
- SELECTIVE REDUCTION OF DONOR-SPECIFIC CYTOTOXIC T LYMPHOCYTE PRECURSORS IN PATIENTS WITH A WELL-FUNCTIONING KIDNEY ALLOGRAFTTransplantation, 1987
- A Randomized Clinical Trial of Cyclosporine in Cadaveric Renal TransplantationNew England Journal of Medicine, 1983